Date:

Company Profile Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are eliminated rapidly by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. Our products are designed to last longer in the body, which allows them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Our diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases. We intend to commercialize these products independently and through strategic alliances with corporate partners.

News 9-17-2009 Bolder BioTechnology Receives $1.2 Million NIH Grant to Continue Development of Long-Acting EPO Analog for Chronic Kidney Disease      Details 9-17-2009 Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome      Details 12-16-2008 Bolder BioTechnology Receives $1.9 million NIH Grant to Continue Development of Long-Acting Growth Hormone Product...      Details 10-15-2008 Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug...      Details View all news